Skip to content
Raltitrexed
Raltitrexed is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against thymidylate synthase.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BA: Folic acid analogs, antimetabolites
— L01BA03: Raltitrexed
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517931531—20
Squamous cell carcinoma of head and neckD000077195——11—2
Colonic neoplasmsD003110C18—1—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Malignant mesotheliomaD000086002—11——2
Liver neoplasmsD008113EFO_1001513C22.0——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16—4———4
Rectal neoplasmsD012004—3———3
ThrombocytopeniaD013921HP_0001873D69.6—1———1
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
Esophageal squamous cell carcinomaD000077277—1———1
Nasopharyngeal neoplasmsD009303—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C803————3
Hyperthermic intraperitoneal chemotherapyD0000842621————1
Myeloid leukemia acuteD015470C92.01————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRALTITREXED
INNraltitrexed
Description
Raltitrexed (Thaltitrexed, Tomudex, TDX, ZD 1694) is an antimetabolite drug used in cancer chemotherapy. It is an inhibitor of thymidylate synthase, and is manufactured by AstraZeneca.
Classification
Small molecule
Drug classantineoplastic thymidylate synthetase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1
Identifiers
PDB2KCE
CAS-ID112887-68-0
RxCUI196239
ChEMBL IDCHEMBL225071
ChEBI ID5847
PubChem CID104758
DrugBankDB00293
UNII IDFCB9EGG971 (ChemIDplus, GSRS)
Target
Agency Approved
TYMS
TYMS
Organism
Homo sapiens
Gene name
TYMS
Gene synonyms
TS
NCBI Gene ID
7298
Protein name
thymidylate synthase
Protein synonyms
TSase
Uniprot ID
Q8WYK4
Mouse ortholog
Tyms (22171)
thymidylate synthase (P07607)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,477 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
269 adverse events reported
View more details